Nanosphere Awarded U.S. Patent for Biobarcode™ Protein Detection Technology
News Dec 16, 2005
Nanosphere, Inc. has announced the company's Biobarcode™ technology has been awarded patent number 6,974,669 by the U.S. Patent and Trademark Office.
Biobarcode™ technology is designed to accomplish for protein detection what PCR has for nucleic acid detection and genomics.
Nanosphere claims that, Biobarcode™ enables the detection of proteins in specimens with sensitivity several orders of magnitude greater than is possible with current technologies including ELISA or mass spectrometry.
Ultra-sensitive protein detection technology will enable development of not only clinical uses for existing biomarkers but also the development of diagnostic tests for previously undetectable biomarkers apparent in many diseases.
This technology will enable earlier detection of cancers (ovarian, prostate, pancreatic, etc.) and neurodegenerative diseases (Alzheimer's, etc.), as well as enable the identification of patients prone to cardiovascular death that are presently missed in diagnosis.
In addition, previously undetected and uncorrelated biomarkers may be developed for both drug development and diagnostic purposes.
"Our focus at Nanosphere is to continuously leverage the power of our nanotechnology platform to bring sophisticated diagnostic and discovery products to the health care and life sciences industries," said William Moffitt, president and CEO, Nanosphere, Inc.
"Today's patent on Biobarcode™ serves to further solidify this core tenant, and enables us to directly address the needs of today, and create the diagnostic and discovery tools of the future."
The biobarcode ™ technology was developed by researchers at Northwestern University, including Dr. Chad Mirkin, professor of chemistry and director of the school's Institute for Nanotechnology.
The company has licensed exclusive rights from Northwestern to existing inventions involving nanoparticle probes and certain other technology developments in the area of biodiagnostics.
The Biobarcode™ patent brings the number of U.S. patents Nanosphere holds to 43 and the company has one hundred applications pending.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018